Abstract:The antiviral endoribonuclease, RNase L, is activated by the mammalian innate immune response to destroy host and viral RNA to ultimately reduce viral gene expression. Herein, we show that RNase L and RNase L-mediated mRNA decay are primarily localized to the cytoplasm. Consequently, RNA-binding proteins (RBPs) translocate from the cytoplasm to the nucleus upon RNase L activation due to the presence of intact nuclear RNA. The re-localization of RBPs to the nucleus coincides with global alterations to RNA processing in the nucleus. While affecting many host mRNAs, these alterations are pronounced in mRNAs encoding type I and type III interferons and correlate with their retention in the nucleus and reduction in interferon protein production. Similar RNA processing defects also occur during infection with either dengue virus or SARS-CoV-2 when RNase L is activated. These findings reveal that the distribution of RBPs between the nucleus and cytosol is dictated by the availability of RNA in each compartment. Thus, viral infections that trigger RNase L-mediated cytoplasmic RNA in the cytoplasm also alter RNA processing in the nucleus, resulting in an ingenious multi-step immune block to protein biogenesis. Ribonuclease L (RNase L) initiates rapid and widespread degradation of cellular mRNAs in response to double-stranded RNA or viral infection. How the mass degradation of mRNAs affects cellular functions is unknown. Herein, we show that RNase L-mediated mRNA decay is predominately localized to the cytoplasm. Consequently, RNA-binding proteins re-localize from the cytoplasm to the nucleus upon RNase L activation. Coinciding with the influx of RNA-binding proteins into the nucleus, we also observe perturbation of nuclear processing of mRNAs, and these processing defects down-regulate key antiviral cytokines, such as type I interferons. Importantly, we observe these processes occurring during dengue virus and SARS-CoV-2 infection, revealing previously unknown aspects of antiviral gene regulation during pathogenic viral infections. Combined, these findings uncover novel mechanisms by which RNase L regulates host gene expression and expand the potential means by which RNase L blocks protein synthesis.

Condensation of RNase L promotes its rapid activation in response to viral infection in mammalian cells

Activation of RNase L is Dependent on OAS3 Expression During Infection with Diverse Human Viruses

RNase L activation in the cytoplasm induces aberrant processing of mRNAs in the nucleus

RNase L activates the NLRP3 inflammasome during viral infections

Molecular bases and specificity behind the activation of the immune system OAS/RNAse L pathway by viral RNA.

RNA regulation of the antiviral protein 2′‐5′‐oligoadenylate synthetase

RNase L-induced bodies sequester subgenomic flavivirus RNAs and re-establish host RNA decay

RNase L-induced bodies sequester subgenomic flavivirus RNAs to promote viral RNA decay

A Novel Mechanism of RNase L Inhibition: Theiler's Virus L* Protein Prevents 2-5A from Binding to RNase L.

Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon-induced antiviral activity.

A proposed molecular mechanism for pathogenesis of severe RNA-viral pulmonary infections

RNA ligands activate the Machupo virus polymerase and guide promoter usage

Discovery and Use of Long dsRNA Mediated RNA Interference to Stimulate Antiviral Protection in Interferon Competent Mammalian Cells

Efficient Dicer processing of virus-derived double-stranded RNAs and its modulation by RIG-I-like receptor LGP2

Actin cytoskeleton remodeling primes RIG-I-like receptor activation

Homologous 2 ',5 '-Phosphodiesterases From Disparate Rna Viruses Antagonize Antiviral Innate Immunity

Exposure of negative-sense viral RNA in the cytoplasm initiates innate immunity to West Nile virus

In situ structures of polymerase complex of mammalian reovirus illuminate RdRp activation and transcription regulation

Initiation of a ZAKα-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L

A closer look at mammalian antiviral condensates

Distinct domain organization and diversity of 2’-5’-oligoadenylate synthetases